Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alterity Therapeutics Ltd. ( (AU:ATH) ) just unveiled an update.
Alterity Therapeutics has completed its Phase 2 clinical trial of ATH434 in early-stage MSA, with results expected by early February 2025. Positive interim data from another Phase 2 trial in advanced MSA suggest ATH434’s potential to modify disease progression. The company’s cash balance was A$4.54M as of December 31, 2024, with a focus on advancing ATH434’s development and presenting its neuroprotective qualities.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. The company is actively working on its lead product, ATH434, which aims to treat conditions such as Multiple System Atrophy (MSA), Parkinson’s disease, and Friedreich’s Ataxia.
YTD Price Performance: 0%
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $29.98M
For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.
